Millions of people worldwide are on the brink of a major breakthrough in HIV prevention, following the approval of a long-acting injectable drug by U.S. health regulators.
On Wednesday, the U.S. Food and Drug Administration (FDA) officially approved lenacapavir, a biannual injection developed by Gilead Sciences, for the prevention of HIV in adults and adolescents at risk of infection. The medication will be marketed under the brand name Yeztugo.
Read: “Kenya’s Forgotten Children”: Youth Champion Arnold Osano Demands Justice for Sickle Cell Victims
Unlike traditional daily HIV-prevention pills like PrEP (pre-exposure prophylaxis), Yeztugo requires only two injections per year — a significant shift in the approach to HIV prevention.
Experts believe this could greatly improve treatment adherence and protect vulnerable populations who struggle with daily medication routines.
“This approval marks a turning point in our global efforts to eliminate HIV,” said Dr. Rochelle Walensky, former Director of the U.S. Centers for Disease Control and Prevention. “A twice-yearly option gives people more flexibility and privacy, especially in communities where stigma remains a barrier.”
According to the World Health Organization, nearly 39 million people were living with HIV in 2022, with about 1.3 million new infections globally that same year.
The burden is particularly heavy in low- and middle-income countries, where consistent access to healthcare and daily medication remains a challenge.
Yeztugo’s long-acting nature could be a game-changer in these regions, offering sustained protection with fewer logistical and behavioral hurdles.
Gilead Sciences has announced that it is working with global health agencies and partners to ensure equitable access to Yeztugo, particularly in high-prevalence areas.
The FDA’s decision comes after promising trial results showed high efficacy and safety of lenacapavir, further fueling hope for ending the decades-long HIV/AIDS epidemic.
For more information on the FDA’s announcement, visit the FDA official statement
Learn about Gilead’s efforts: Gilead Sciences – Lenacapavir Overview
Global HIV Statistics: WHO HIV Factsheet
Do you want to be published? Email info@thedailywhistle.co.ke or Whatsapp 0721930260
